Dana E. Angelini - Concepedia

Author

Dana E. Angelini

Cleveland Clinic ORCID

Also Known As

D Angelini, D. Angelini, D.E. Angelini, Dana Angelini, Dana E Angelini, Dana E. Angelini, Dana Elizabeth Angelini

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic University Hospitals Seidman Cancer Center The University of Texas MD Anderson Cancer Center University of Colorado Denver Duke Cancer Institute

About

Dana E. Angelini is an author at Cleveland Clinic specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	709
2	Immunology	4	4	63
3	Health Sciences	3	3	322
4	Metabolism	1	1	14
5	Obstetrics	1	1	34

Dana E. Angelini

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018 Michael B. Streiff, Bjorn Holmstrom, Dana E. Angelini, Journal of the National Comprehensive Cancer Network Cancer ManagementNccn Guidelines InsightsPathologyPharmacotherapyCancer-associated Vte	2018	241
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer Remco J. Molenaar, Surbhi Sidana, Tomas Radivoyevitch, Journal of Clinical Oncology	2017	154
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Michael B. Streiff, Bjorn Holmstrom, Dana E. Angelini, PubMed Surgical OncologyCancer ManagementPharmacotherapyThrombosisVenous Thrombosis	2021	152
Bleeding incidence and risk factors among cancer patients treated with anticoagulation Dana E. Angelini, Tomas Radivoyevitch, Keith R. McCrae, American Journal of Hematology	2019	145
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology Michael B. Streiff, Bjorn Holmstrom, Dana E. Angelini, Journal of the National Comprehensive Cancer Network Cancer ManagementPharmacotherapyCancer-associated VteVersion 2.2024Thrombosis	2024	143
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study Fahrettin Covut, Ramsha Ahmed, Sanchit Chawla, British Journal of Haematology	2021	41
Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine Remco J. Molenaar, Christopher Pleyer, Tomas Radivoyevitch, Leukemia MedicineIodine Deficiency DisordersRadioactive IodineThyroid DiseaseThyroid Disorders	2017	36
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial Margaret V. Ragni, Scott D. Rothenberger, Robert Feldman, The Lancet Haematology ThrombosisHematologyGynecologyHemostasisCoagulopathy	2023	34
Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation Young Jun Shim, Victor Chatterjee, Shadi Swaidani, Blood Advances	2021	33
Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience Shyam K. Poudel, Deborah Y. Park, Xuefei Jia, Journal of Thrombosis and Haemostasis ThrombosisPulmonary EmbolismVenous DiseaseVenous ThrombosisMedicine	2019	27

Page 1